CAGNETTA, ANTONIA
 Distribuzione geografica
Continente #
EU - Europa 5.887
AS - Asia 618
NA - Nord America 268
SA - Sud America 55
AF - Africa 12
OC - Oceania 4
Totale 6.844
Nazione #
IT - Italia 5.747
SG - Singapore 269
US - Stati Uniti d'America 248
CN - Cina 167
VN - Vietnam 121
FR - Francia 43
BR - Brasile 29
FI - Finlandia 24
HK - Hong Kong 22
DE - Germania 21
AR - Argentina 16
GB - Regno Unito 12
CA - Canada 11
BD - Bangladesh 10
IQ - Iraq 7
CH - Svizzera 5
ES - Italia 5
IN - India 5
MA - Marocco 5
MX - Messico 5
NL - Olanda 5
UA - Ucraina 5
ID - Indonesia 4
AU - Australia 3
EC - Ecuador 3
GR - Grecia 3
IE - Irlanda 3
JP - Giappone 3
PY - Paraguay 3
AT - Austria 2
PL - Polonia 2
SE - Svezia 2
VE - Venezuela 2
AO - Angola 1
BH - Bahrain 1
CL - Cile 1
CO - Colombia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
HN - Honduras 1
HR - Croazia 1
KE - Kenya 1
KR - Corea 1
LB - Libano 1
LT - Lituania 1
MG - Madagascar 1
MT - Malta 1
NI - Nicaragua 1
PF - Polinesia Francese 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TR - Turchia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
TZ - Tanzania 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 6.844
Città #
Genova 3.163
Genoa 1.700
Rapallo 484
Vado Ligure 350
Singapore 140
San Jose 80
Ashburn 53
Ho Chi Minh City 41
Lauterbourg 38
Beijing 32
Hanoi 25
Helsinki 24
Hong Kong 22
Frankfurt am Main 19
Council Bluffs 16
New York 11
Santa Clara 10
Bordighera 8
Los Angeles 8
Da Nang 7
Tianjin 6
Haiphong 5
London 5
Montreal 5
Turin 5
Zurich 5
Amsterdam 4
Buffalo 4
Biên Hòa 3
Cardiff 3
City of London 3
Denver 3
Kyiv 3
Madrid 3
Nha Trang 3
Orem 3
Paris 3
Perugia 3
São Paulo 3
Tokyo 3
Athens 2
Belo Horizonte 2
Bắc Ninh 2
Can Tho 2
Casablanca 2
Chennai 2
Chicago 2
Dublin 2
Hải Dương 2
Lambaré 2
Milan 2
Ninh Bình 2
Nuremberg 2
Rio de Janeiro 2
Rome 2
San Juan 2
Stockholm 2
Sydney 2
Toronto 2
Agadir 1
Ankara 1
Antananarivo 1
Aracaju 1
Arima 1
Aurangabad 1
Bady Bassitt 1
Baghdad 1
Bandung 1
Barquisimeto 1
Barranquilla 1
Basra 1
Belgrade 1
Berisso 1
Blida 1
Boa Vista 1
Bolesławiec 1
Botucatu 1
Brooklyn 1
Buenos Aires 1
Bình Phước 1
Cairo 1
Cape Town 1
Changchun 1
Chapada Gaúcha 1
Cheonan 1
Ciudad del Este 1
Columbia 1
Congonhas 1
Copenhagen 1
Cuautitlán Izcalli 1
Cuenca 1
Dar es Salaam 1
Dhaka 1
Elizabeth 1
Emiliano Zapata 1
Erbil 1
Formosa 1
Guayaquil 1
Hangzhou 1
Hat Yai 1
Totale 6.385
Nome #
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 258
APO866 activity in hematologic malignancies: a preclinical in vitro study. 245
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment 242
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 240
Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors and DNA repair. 229
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 218
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 203
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. 198
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more. 191
ANTITUMOR ACTIVITY OF NAMPT INHIBITION AND SYNERGY WITH CYCLOSPORIN A AND HDACIS TO PROMOTE APOPTOSIS IN PRIMARY LEUKEMIC CELLS 189
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 186
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 179
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 176
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 173
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 171
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 166
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 164
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 163
Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. 162
Nicotinamide Phosphoribosyltransferase As A Target In Inflammation-Related Disorders. 160
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 156
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 154
New insights into biology of chronic myeloid leukemia: implications in therapy. 148
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib 148
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 146
Targeting NAD(+) Salvage Pathway Induces Autophagy in Multiple Myeloma Cells 145
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications 145
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma 139
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells via mTORC1 and Extracellular Signal-Regulated Kinase (ERK1/2) Inhibition 138
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. 138
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. 138
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. 132
MiR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth 129
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 123
NAD+ METABOLISM RESTRICTION BOOSTS HIGH-DOSE MELPHALAN EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA 121
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma 121
Intracellular NAD+ depletion induces autophagic-death in Multiple Myeloma cells 121
A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML 111
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells 108
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 106
Synergistic Interaction Between P-glycoprotein Inhibitors and APO866 in Primary Leukemic Cells 104
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation 88
Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma 70
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 59
Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma 52
Totale 6.953
Categoria #
all - tutte 21.428
article - articoli 21.428
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.856


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021139 0 0 0 0 0 0 0 0 0 53 51 35
2021/2022548 21 26 37 69 24 44 30 109 28 47 29 84
2022/2023601 67 67 3 73 97 86 6 37 85 12 64 4
2023/2024391 13 53 14 50 41 80 22 38 10 5 28 37
2024/20251.047 38 64 29 74 96 99 107 230 33 46 106 125
2025/20261.654 234 52 103 207 241 149 273 83 154 158 0 0
Totale 6.953